IMMUNITYBIO, INC. Payments to Develop Software
IMMUNITYBIO, INC. (IBRX) reported Payments to Develop Software of $34.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaymentsToDevelopSoftware · last filed 2026-08-04
- IMMUNITYBIO, INC. payments to develop software for the quarter ending 2026-06-30 was $23.00K.
- IMMUNITYBIO, INC. payments to develop software for the quarter ending 2026-03-31 was $11.00K.
- IMMUNITYBIO, INC. payments to develop software for the quarter ending 2025-12-31 was $372.00K.
- IMMUNITYBIO, INC. payments to develop software for the quarter ending 2025-09-30 was $34.00K.
- IMMUNITYBIO, INC. payments to develop software for fiscal 2025 was $406.00K.
- IMMUNITYBIO, INC. payments to develop software for fiscal 2024 was $0.00.
- IMMUNITYBIO, INC. payments to develop software for fiscal 2023 was $0.00.
| Period end | Payments to Develop Software 3 month | Payments to Develop Software 6 month | Payments to Develop Software 9 month | Payments to Develop Software 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $34.00K 10-Q · filed 2026-08-04 | $406.00K derived: sum of 3 quarters · filed 2026-08-04 | $440.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $11.00K 10-Q · filed 2026-05-07 | $383.00K derived: sum of 2 quarters · filed 2026-05-07 | $417.00K derived: sum of 3 quarters · filed 2026-05-07 | $417.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $406.00K derived: sum of 2 quarters · filed 2026-02-23 | $406.00K derived: sum of 3 quarters · filed 2026-08-04 | $406.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $34.00K derived: sum of 2 quarters · filed 2026-08-04 | $34.00K 10-Q · filed 2025-11-05 | $34.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |